Clinical Trial Update: Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma [Phase 3]

View source ↗

Summary

This is a Phase 3 randomized trial comparing G-CSF alone versus intermediate-dose Ara-C plus G-CSF mobilization in patients with Hodgkin lymphoma or non-Hodgkin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Filgrastim (filgrastim)

Snippet

Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology | Conditions: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma | Phase 3 | Status: UNKNOWN